Clinical Trial Search

Primary: Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) => 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 72 — 0 percentage of participants

Primary: Time to Treatment Failure (Measured in Days) — 196.9; 225.2; 182.3 days

Primary: Overall Survival — 24.5; 22.5 months

Primary: Overall Survival — 20.0; 19.2 Months

Primary: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48 — 28.5; 0 Percentage of Participants — p=<0.0001

Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) — 7; 7; 2; 0 Subjects

Primary: Number of Participants With One or More Drug-related Serious Adverse Events — 0 Participants

Primary: Overall Analgesic Efficacy - Sum of Pain Intensity Difference and Pain Relief Scores Over Six Hours (SPRID6) — 529.4; 427.3; 60.0 units on a scale — p=<0.001

Primary: Improvement in Diabetes and/or Glucose Intolerance. — 15 participants

Primary: Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort — 1; 48 participants

Primary: Time to Occurrence of Disease Worsening or Death up to End of Study. — 10; 18; 22; 40 participants with event — p=0.2110

Primary: Progression Free Survival — 4.6; 3.4 months

Primary: Change From Baseline in Average Subject-Reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period — -2.0; -1.0 units on a scale…

Primary: Change From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 30 Weeks — -3.4; -2.4 units on a scale — p=<0.001

Primary: Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis…